亞洲 ADC 抗體藥物複合體
抗體藥物複合體：把化療藥綁在抗體上，精準送進癌細胞。
40追蹤資產
9已核准
Enhertu (DS-8201)最領先資產
Daiichi Sankyo · 已核准
US$ 22,000M最大已揭露授權總額上限
首付：US$ 4,000M
這個賽道在做什麼
ADC 由三部分組成：認得癌細胞的抗體、負責連接的連接子，以及殺傷力強的藥物酬載。抗體帶著藥物找到癌細胞、被細胞吞進去後才釋放藥物，所以能用更高的殺傷力、換到比傳統化療少的全身副作用。這幾年大藥廠為 ADC 付出的授權金額屢創新高，亞洲公司，特別是中國，已經是全球 ADC 臨床資產最多的來源。
重點看這裡
- 追蹤資產共 40 項。
- 已核准資產共 9 項。
- 資產來源涵蓋 3 個國家或地區。
- 單獨揭露首付最高為 Daiichi Sankyo，2023-10-19，US$ 4000M。
階段分布
已核准9 9
三期31 31
國家分布
China33 33
Japan6 6
South Korea1 1
資產表
| 排名 | 資產 | 國際非專利藥名 | 原研公司 | 國家 | 標的 | 載荷 | 最高階段 | 適應症 | 試驗編號 | 亞洲以外權利持有人 | 交易日期 | 最新事件 | 最新事件日期 | 來源 | 來源日期 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3 | Padcev (ASG-22ME) [co-originated] | enfortumab vedotin | Astellas Pharma (Japan) co-developed with Seagen (US, now Pfizer) | Japan (co-originated with US company) | Nectin-4 | MMAE (tubulin inhibitor) | Approved (FDA first approval Dec 2019) | Urothelial cancer; newest: perioperative MIBC with pembrolizumab regardless of cisplatin eligibility | NCT04700124 (EV-304); NCT04223856 (EV-302) | Co-owned Astellas & Pfizer (Seagen acquired by Pfizer 2023-12-14) - not a license-out | FDA approved Padcev + Keytruda neoadjuvant/adjuvant MIBC regardless of cisplatin eligibility (EV-304) | 2026-07-13 | newsroom.astellas.com www.chemexpress.com | 2026-07-13 | |
| 2 | Datroway (DS-1062) | datopotamab deruxtecan | Daiichi Sankyo | Japan | TROP2 | DXd (topoisomerase I inhibitor) | Approved (FDA first approval Jan 2025) | Breast cancer, NSCLC; newest: 1L metastatic TNBC not candidates for PD-(L)1 | NCT05374512 (TROPION-Breast02) | AstraZeneca (Daiichi keeps Japan) | 2020-07 | US approval in 1L TNBC (TROPION-Breast02) | 2026-05-26 | www.lse.co.uk clinicaltrials.gov www.chemexpress.com | 2026-05-26 |
| 1 | Enhertu (DS-8201) | trastuzumab deruxtecan | Daiichi Sankyo | Japan | HER2 | DXd (topoisomerase I inhibitor) | Approved (FDA first approval Dec 2019; also NMPA etc.) | HER2+ / HER2-low breast cancer and others; newest: HER2+ early breast cancer (neoadjuvant DB-11, adjuvant DB-05) | NCT04622319 (DESTINY-Breast05); NCT05113251 (DESTINY-Breast11) | AstraZeneca (global co-development/commercialisation; Daiichi keeps Japan) | 2019-03 | NMPA approved adjuvant HER2+ early BC (DB-05), 9th China indication; FDA approved DB-05 + DB-11 early-BC indications on 2026-05-15 | 2026-09-29 | news.10jqka.com.cn www.astrazeneca.com www.chemexpress.com | 2026-10-09 |
| 6 | Aiweida (SHR-A1811) | trastuzumab rezetecan | Jiangsu Hengrui Pharmaceuticals | China | HER2 | SHR9265 (topoisomerase I inhibitor) | Approved (NMPA, first approval May 2025; 3 China indications) | HER2-mutant NSCLC (first); HER2+ breast cancer; HER2+ colorectal cancer (3rd, 2026-08) | NCT06057610; NCT06123494; SHR-A1811-III-309 (HORIZON CRC01) | Glenmark (emerging markets only; excludes Greater China, US, Canada, Europe, Japan, Russia/CIS) | 2025-09-24 | NMPA approved 3rd indication HER2+ CRC; HER2-low BC sNDA accepted with priority review 2026-07-08 | 2026-08-06 | static.cninfo.com.cn news.10jqka.com.cn www.theweek.in | 2026-08-06 |
| 8 | Meiyouheng (MRG003) | becotatug vedotin | Lepu Biopharma / Shanghai Miracogen | China | EGFR | MMAE (tubulin inhibitor) | Approved (NMPA) | R/M nasopharyngeal carcinoma after >=2 lines chemo and PD-(L)1 | NCT05751512 (Ph3 SCCHN, ongoing); NCT06976190 (Ph3 NPC combo) | NMPA approval, first approved EGFR ADC (pivotal Ph2: ORR 30.2% vs 11.5%) | 2025-10-30 | global.pharmcube.com www.chemexpress.com | 2025-11-04 | ||
| 4 | Aidixi (RC48) | disitamab vedotin | RemeGen | China | HER2 | MMAE (tubulin inhibitor) | Approved (NMPA, first approval Jun 2021) | HER2+ gastric cancer (first); newest: 1L HER2-expressing urothelial carcinoma with toripalimab | NCT05302284 (RC48-C016) | Seagen, now Pfizer (worldwide ex-RemeGen territory; RemeGen keeps Asia excl. Japan & Singapore) | 2021-08-09 | NMPA approved DV + toripalimab 1L HER2-expressing la/mUC (RC48-C016: PFS 13.1 vs 6.5 mo; OS 31.5 vs 16.9 mo) | 2026-05-22 | news.qq.com www.cancernetwork.com www.businesswire.com | 2026-05-22 |
| 9 | Yizekang (BL-B01D1 / BMS-986507) | izalontamab brengitecan | Sichuan Baili Pharmaceutical (Biokin) / SystImmune | China | EGFR x HER3 (bispecific) | Ed-04 (topoisomerase I inhibitor) | Approved (NMPA conditional; first approved bispecific ADC) | R/M nasopharyngeal carcinoma (2026-06-22); 2L R/M ESCC (2026-07-17) | NCT06118333 (NPC Ph3); NCT06304974 (ESCC Ph3); NCT07100080 (BMS global Ph3) | Bristol Myers Squibb (ex-mainland China) | 2023-12 (announced 2023-12-11/12; $800M upfront) | NMPA approved 2nd indication (ESCC) 25 days after NPC approval | 2026-07-17 | www.biochempeg.com www.biopharminternational.com www.biopharminternational.com | 2026-08-20 |
| 5 | Jiatailai (SKB264 / MK-2870) | sacituzumab tirumotecan | Sichuan Kelun-Biotech | China | TROP2 | KL610023 (topoisomerase I inhibitor) | Approved (NMPA, first approval Nov 2024; 4 China approvals in breast cancer & NSCLC) | Breast cancer; NSCLC (China). US BLA (endometrial) under priority review | NCT06132958 (TroFuse-005) | Merck & Co./MSD (ex-Greater China) | 2022 (reported 2022-05-19) | TroFuse-005 Ph3 (endometrial) OS 19.0 vs 12.1 mo published in Lancet/ESMO 2026; FDA BLA accepted, PDUFA 2027-06-15 | 2026-10-26 | www.biopharminternational.com gxpnews.net www.chemexpress.com | 2026-10-26 |
| 7 | Shutailai (A166) | trastuzumab botidotin | Sichuan Kelun-Biotech | China | HER2 | Duostatin-5 (tubulin inhibitor; MMAF-class) | Approved (NMPA) | Unresectable/metastatic HER2+ breast cancer after >=1 prior therapy | NCT06968585 (Ph3 vs T-DM1) | NMPA marketing approval | 2025-10-17 | www.thepharmaletter.com www.chemexpress.com clinicaltrials.gov | 2025-10-17 | ||
| 13 | DP303c | trastuzumab envedotin | CSPC Pharmaceutical Group | China | HER2 | MMAE (tubulin inhibitor; DAR ~2) | Phase 3 complete - NDA under NMPA review | Unresectable/metastatic HER2+ breast cancer after >=1 anti-HER2 therapy | NCT06313086 (Ph3 vs T-DM1) | NMPA accepted NDA (Ph3 PFS superior to T-DM1) | 2026-07-17 | doc.irasia.com db.antibodysociety.org clinicaltrials.gov | 2026-07-17 | ||
| 10 | DB-1303 / BNT323 | trastuzumab pamirtecan | Duality Biotherapeutics (DualityBio) | China | HER2 | P1003 / pamirtecan (topoisomerase I inhibitor) | Phase 3 complete - BLA under NMPA review | 2L HER2+ unresectable/metastatic breast cancer | NCT06265428 (DB-1303-O-3001); NCT06018337 (DYNASTY-Breast02); NCT06340568 (global Ph3 endometrial) | BioNTech (ex-mainland China, HK, Macau) | 2023-04-03 | NMPA accepted BLA (Ph3 vs T-DM1 met PFS) | 2026-04-09 | www.onclive.com www.biontech.com | 2026-04-09 |
| 14 | HS-20093 / GSK5764227 | risvutatug rezetecan | Hansoh Pharmaceutical | China | B7-H3 | Topoisomerase I inhibitor | Phase 3 complete - BLA under NMPA review | SCLC progressed after platinum chemotherapy | NCT06498479 (ARTEMIS-008); NCT06526624; NCT06935409 | GSK (ex-mainland China, HK, Macau, Taiwan) | 2023-12 | NMPA accepted BLA; ARTEMIS-008 OS 18.5 vs 10.3 mo (HR 0.46) at WCLC 2026 | 2026-09-02 | www1.hkexnews.hk ascopost.com www.biospace.com db.antibodysociety.org | 2026-09-16 |
| 11 | IBI343 / TAK-921 | arcotatug tavatecan | Innovent Biologics | China | CLDN18.2 | Exatecan (topoisomerase I inhibitor) | Phase 3 complete - NDA under NMPA priority review | CLDN18.2+ gastric/GEJ adenocarcinoma after >=2 prior lines | NCT06238843 (G-HOPE-001, China/Japan); NCT07066098 (Ph3 pancreatic) | Takeda (ex-Greater China) | 2025-10-21 | Ph3 met PFS at interim; NMPA accepted NDA with priority review (world's first CLDN18.2 ADC filing) | 2026-06-04 | www.fiercebiotech.com www.takeda.com www.chemexpress.com | 2026-06-30 |
| 15 | YL201 | tambotatug pelitecan | MediLink Therapeutics | China | B7-H3 | Topoisomerase I inhibitor (TMALIN platform, DAR 8) | Phase 3 complete - NDA accepted by China CDE | Relapsed SCLC after 1 prior platinum line | NCT06612151 (TAISHAN-302); NCT06629597 (TAISHAN-301 NPC); NCT07739758; NCT07487896 | Roche (worldwide ex-mainland China, HK, Macau) | 2026-01 | TAISHAN-302 Ph3: OS 13.3 vs 9.4 mo (HR 0.46), WCLC 2026 + NEJM; China NDA accepted; Roche to start global Ph3 | 2026-09-13 | www.roche.com ascopost.com | 2026-09-13 |
| 12 | LM-302 (TPX-4589) | tecotabart vedotin | Sino Biopharmaceutical (LaNova Medicines subsidiary) (wholly owned by Sino Biopharmaceutical) | China | CLDN18.2 | MMAE (tubulin inhibitor) | Phase 3 complete (interim) - NDA under NMPA priority review | CLDN18.2+ gastric/GEJ adenocarcinoma after >=2 prior lines | NCT06351020 (Ph3 3L+); NCT07385703 (Ph3 1L combo) | None currently (Turning Point/BMS license of May 2022 terminated by BMS Oct 2024) | 2022-05 (terminated 2024-10) | NMPA accepted NDA (priority review); full Ph3 data expected early 2027 | 2026-06-23 | www.zhitongcaijing.com www.apexonco.com www.chemexpress.com | 2026-06-23 |
| 28 | JSKN003 | Alphamab Oncology | China | HER2 (biparatopic) | Topoisomerase I inhibitor | Phase 3 (4 Ph3 trials) | HER2-low mBC; PROC; HER2+ mBC vs T-DM1; HER2+ CRC | NCT06079983; NCT06751485; NCT06846437; NCT07384377 | 4th Ph3 (HER2+ CRC) first patient dosed Feb 2026; FDA BTD in HER2-expressing PROC (Dec 2025) | 2026-03-25 | www1.hkexnews.hk www.pharmafocusasia.com | 2026-03-25 | |||
| 31 | TQB2102 | rolditamig deuderuxtecan (name per press; INN status not confirmed) | Chia Tai Tianqing (Sino Biopharmaceutical) | China | HER2 (biparatopic) | Topoisomerase I inhibitor | Phase 3 (5 Ph3 trials) | HER2-low mBC; HER2+ mBC vs T-DM1; neoadjuvant HER2+ BC | NCT06561607; NCT07008976; NCT07003074; NCT07043725 | Cipla (India, South Africa + 5 emerging markets only) | 2026-08-31 | Cipla license for emerging markets | 2026-08-31 | www.outsourcedpharma.com db.antibodysociety.org | 2026-08-31 |
| 17 | SYS6010 | CSPC Pharmaceutical Group (CSPC Megalith) | China | EGFR | Topoisomerase I inhibitor | Phase 3 (positive topline) | EGFR-mutant advanced NSCLC after EGFR-TKI | NCT06927986 (SYNSTAR-01); 8 further Ph3 on CT.gov | SYNSTAR-01 Ph3 met PFS vs platinum chemo; OS trend positive | 2026-08-26 | filingreader.com clinicaltrials.gov | 2026-08-26 | |||
| 20 | DS-6000 / MK-5909 (R-DXd) | raludotatug deruxtecan | Daiichi Sankyo | Japan | CDH6 | DXd (topoisomerase I inhibitor) | Phase 3 (Ph2/3) | Platinum-resistant ovarian cancer; 1L/2L maintenance ovarian (new Ph3s) | NCT06161025 (REJOICE-Ovarian01); NCT07776691; NCT07743164; NCT07791732 | Merck & Co./MSD (Daiichi keeps Japan) | 2023-10 | New Merck/Daiichi Ph3 trials in ovarian maintenance started Sep-Oct 2026 (CT.gov); Ph2 part ORR 50.5% (ESMO 2025) | 2026-10-07 | www.merck.com clinicaltrials.gov | 2026-10-07 |
| 18 | DS-7300 / MK-2400 (I-DXd) | ifinatamab deruxtecan | Daiichi Sankyo | Japan | B7-H3 | DXd (topoisomerase I inhibitor) | Phase 3 | Relapsed ES-SCLC (IDeate-Lung02); also ESCC, mCRPC | NCT06203210 (IDeate-Lung02); NCT06644781; NCT06925737 | Merck & Co./MSD (global co-development; Daiichi keeps Japan) | 2023-10 | US accelerated-approval BLA (Ph2 IDeate-Lung01) voluntarily withdrawn; filing now depends on Ph3 IDeate-Lung02 | 2026-09-25 | www.merck.com | 2026-09-25 |
| 19 | U3-1402 / MK-1022 (HER3-DXd) | patritumab deruxtecan | Daiichi Sankyo | Japan | HER3 | DXd (topoisomerase I inhibitor) | Phase 3 | HR+/HER2- metastatic breast cancer (HERTHENA-Breast04); EGFRm NSCLC (HERTHENA-Lung02, OS not significant) | NCT07060807 (HERTHENA-Breast04); NCT05338970 (HERTHENA-Lung02) | Merck & Co./MSD (Daiichi keeps Japan) | 2023-10 | HERTHENA-Breast04 Ph3 enrolling (started 2025-07-21); US NSCLC BLA withdrawn 2025-05 | 2026-06-04 | www.onclive.com www.indianpharmapost.com | 2026-06-04 |
| 21 | DB-1311 / BNT324 | Duality Biotherapeutics (DualityBio) | China | B7-H3 | Topoisomerase I inhibitor (DAR 6) | Phase 3 (global) | Metastatic castration-resistant prostate cancer vs docetaxel | NCT07365995 | BioNTech (ex-mainland China, HK, Macau; Duality US co-development option) | 2023-04-03 | Global Ph3 in mCRPC started (CT.gov start 2026-04-22) | 2026-04-22 | www.fiercebiotech.com clinicaltrials.gov www.biontech.com | 2026-04-22 | |
| 30 | HS-20089 / GSK5733584 | Hansoh Pharmaceutical | China | B7-H4 | Topoisomerase inhibitor | Phase 3 | Platinum-resistant recurrent epithelial ovarian cancer; new Ph3 in platinum-sensitive OC | NCT06855069; NCT07821606 | GSK (ex-mainland China, HK, Macau, Taiwan) | 2023-10-20 | New Ph3 (with bevacizumab, PSOC) registered, start 2026-11-01 | 2026-11-01 | www.gsk.com clinicaltrials.gov | 2026-11-01 | |
| 35 | IBI354 | Innovent Biologics | China | HER2 | Not disclosed in sources opened (hydrophobic payload, DAR 8) | Phase 3 | Platinum-resistant ovarian cancer (HeriCare-Ovarian01); 1L HER2+ mBC (HeriCare-Breast01) | NCT06834672; NCT07377643 | ESMO 2026 Ph2 data (1L HER2+ BC + pertuzumab, ORR 95%) | 2026-10-25 | www.prnewswire.com clinicaltrials.gov | 2026-10-25 | |||
| 32 | SHR-A1904 | Jiangsu Hengrui Pharmaceuticals | China | CLDN18.2 | Topoisomerase I inhibitor | Phase 3 | 2L CLDN18.2+ advanced gastric/GEJ cancer | NCT06649292 | Merck KGaA (option for ex-China license; current status not verified) | 2023-10-30 | Ph3 recruiting (CT.gov); NMPA combo IND approvals 2025-06-20 | 2025-06-20 | www.biospace.com static.cninfo.com.cn clinicaltrials.gov | 2025-06-21 | |
| 37 | SHR-A1912 | Jiangsu Hengrui Pharmaceuticals | China | CD79b | SHR9265 (topoisomerase I inhibitor) | Phase 3 | R/R DLBCL (+ R-GemOx) | NCT06929624 | Ph3 active, not recruiting (CT.gov update 2026-09-25) | 2026-09-25 | adcdb.idrblab.cn clinicaltrials.gov | 2026-09-25 | |||
| 29 | SHR-A1921 | tizetatug rezetecan | Jiangsu Hengrui Pharmaceuticals | China | TROP2 | SHR9265 / rezetecan (topoisomerase I inhibitor) | Phase 3; NCT06394492 RECRUITING (status as of 2024-08-09) Registry | Platinum-resistant recurrent epithelial ovarian cancer | NCT06394492; NCT06211023 | Ph3 in PROC recruiting (CT.gov) | 2024-05-10 | db.antibodysociety.org clinicaltrials.gov | 2024-05-10 | ||
| 33 | SHR-A2009 | Jiangsu Hengrui Pharmaceuticals | China | HER3 | Topoisomerase I inhibitor | Phase 3 | EGFR-mutant advanced NSCLC (post-TKI; and 1L + aumolertinib) | NCT06671379; NCT07183189; NCT07895992 | New Ph3 (with bevacizumab, nsqNSCLC) registered, start 2026-11-30 | 2026-11-30 (planned) | db.antibodysociety.org clinicaltrials.gov | 2026-10 | |||
| 34 | SHR-A2102 | Jiangsu Hengrui Pharmaceuticals | China | Nectin-4 | SHR169265 (topoisomerase I inhibitor) | Phase 3 | Advanced urothelial carcinoma; MIBC; platinum-pretreated (NCT07418749) | NCT06738251; NCT07393542; NCT06879145; NCT07418749 | Ph1 published in Lancet Oncology | 2026-09-09 | stock.10jqka.com.cn db.antibodysociety.org clinicaltrials.gov | 2026-09-09 | |||
| 16 | CMG901 / AZD0901 | sonesitatug vedotin | KYM Biosciences (JV: Keymed Biosciences 70% / Lepu Biopharma 30%) | China | CLDN18.2 | MMAE (per INN suffix -vedotin) | Phase 3 (positive topline) | 2L+ CLDN18.2+ gastric/GEJ/esophageal adenocarcinoma | NCT06346392 (CLARITY-Gastric01); NCT07431281 | AstraZeneca (global incl. China) | 2023-02-23 | CLARITY-Gastric01 global Ph3 positive: OS benefit (dual primary OS in 3L+ met; PFS not significant) | 2026-07-28 | www1.hkexnews.hk www.pharmafocusasia.com clinicaltrials.gov | 2026-07-28 |
| 26 | MRG002 | Lepu Biopharma / Shanghai Miracogen | China | HER2 | MMAE (tubulin inhibitor) | Phase 3; NCT05754853 RECRUITING (status as of 2023-04-13) Registry | HER2+ la/m urothelial cancer (also HER2+ BC Ph3, status unknown) | NCT05754853; NCT04924699 | Ph3 in HER2+ UC registered as recruiting (no newer verified event found) | 2023-04-13 | db.antibodysociety.org clinicaltrials.gov | 2023-04-13 | |||
| 25 | LCB14 / FS-1502 / IKS014 | caxmotabart entudotin | LigaChem Biosciences (formerly LegoChem Biosciences) | South Korea | HER2 | MMAF (tubulin inhibitor; site-specific, DAR 2) | Phase 3 (China, by Fosun); NCT05755048 UNKNOWN (status as of 2023-09-01) Registry | HER2+ mBC vs T-DM1 | NCT05755048 (Fosun Ph3); NCT05872295 (Iksuda Ph1) | Iksuda Therapeutics (worldwide ex-Greater China & Korea); Fosun Pharma holds Greater China | 2022-01-10 (Iksuda) | Ligachem R&D Day: Fosun Ph3 ongoing in China; IKS014 global Ph1 RP2D 105 mg/m2, ORR 35-40% | 2026-07-08 | biz.newdaily.co.kr db.antibodysociety.org www.businesswire.com | 2026-07-08 |
| 27 | 9MW2821 | bulumtatug fuvedotin | Mabwell (Shanghai) Bioscience | China | Nectin-4 | MMAE (tubulin inhibitor) | Phase 3 (4 Ph3 trials) | 2L+ urothelial carcinoma (enrollment complete); cervical; 1L UC + toripalimab; TNBC | NCT06196736; NCT06592326; NCT06692166; NCT07556848 | 4 Ph3 ongoing; UC/CC interim analyses planned 2H26, then pre-NDA with NMPA | 2026-08-30 | www1.hkexnews.hk db.antibodysociety.org www.biospace.com | 2026-08-30 | ||
| 39 | YL202 / BNT326 | MediLink Therapeutics | China | HER3 | Not verified | Phase 3 | HR+/HER2- breast cancer; EGFR-sensitizing NSCLC vs docetaxel | NCT07461454; NCT07416994 | BioNTech (ex-China, HK, Macau) - current status not re-verified | 2023 (~Oct, per FierceBiotech) | Two pivotal Ph3 trials started in China (Mar 2026) | 2026-03-18 | www.fiercebiotech.com clinicaltrials.gov | 2026-03-18 | |
| 38 | MHB088C | Minghui Pharmaceutical | China | B7-H3 | Not verified | Phase 3 | Relapsed SCLC vs physician's choice | NCT06954246 (Qilu-sponsored) | Minghui retains ex-Greater China rights (Qilu licensed Greater China) | 2025-05 (Qilu, Greater China) | Ph3 recruiting (started 2025-06-04) | 2025-06-04 | www.fiercebiotech.com www.apexonco.com clinicaltrials.gov | 2025-06-18 | |
| 36 | FDA018 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical | China | TROP2 | SN-38 (topoisomerase I inhibitor) | Phase 3 | Taxane-pretreated la/m TNBC | NCT06519370 | Ph3 active, not recruiting (CT.gov update 2026-01-22) | 2026-01-22 | db.antibodysociety.org clinicaltrials.gov | 2026-01-22 | |||
| 23 | HLX43 | Shanghai Henlius Biotech | China | PD-L1 | Topoisomerase I inhibitor (linker in-licensed) | Phase 3 (global Ph2/3) | Previously treated advanced/metastatic squamous NSCLC vs docetaxel | NCT07459751 | First patient dosed in global Ph2/3 (HLX43 +/- HLX07) | 2026-05-28 | www.hkexnews.hk clinicaltrials.gov | 2026-05-28 | |||
| 40 | JS107 | Shanghai Junshi Biosciences (TopAlliance) | China | CLDN18.2 | MMAE (tubulin inhibitor) | Phase 3 | 2L+ CLDN18.2+ gastric/GEJ adenocarcinoma; 1L combo | NCT07284134; NCT07584135 | Ph3 started (2025-12-24); 1L combo Ph3 started 2026-05-28 | 2026-05-28 | adcdb.idrblab.cn clinicaltrials.gov | 2026-05 | |||
| 24 | BL-M07D1 (T-Bren) | Sichuan Baili Pharmaceutical (Biokin) / SystImmune | China | HER2 | Ed-04 (topoisomerase I inhibitor) | Phase 3 (9 Ph3 trials) | HER2+ mBC vs T-DM1 (most advanced); also HER2-low BC, NSCLC, BTC, CRC, PROC | NCT06316531; NCT06957886; NCT06830889; NCT06891833; NCT07178795; NCT07545460 | 9th Ph3 started (HER2-expressing PROC); CDE BTDs in HER2+ GC and BTC | 2026-09-30 | pdf.dfcfw.com oncodaily.com clinicaltrials.gov | 2026-09-30 | |||
| 22 | ZL-1310 | zocilurtatug pelitecan | Zai Lab (built on TMALIN platform) | China | DLL3 | Camptothecin derivative (topoisomerase I inhibitor) | Phase 3 (global) | 2L+ ES-SCLC (DLLEVATE) | NCT07218146 (DLLEVATE); NCT07796100 (1L Ph3, not yet recruiting) | Zai Lab retains global rights (Amgen = combination-trial collaborator only) | DLLEVATE on track, enrollment complete expected 1H27; potential US accelerated filing 2027 | 2026-08-06 | www.biospace.com www.businesswire.com clinicaltrials.gov | 2026-08-06 |
授權交易
| 日期 | 授權方 | 授權方國家 | 合作方 | 資產或平台 | 標的 | 簽約時階段 | 首付（百萬美元） | 總額（百萬美元） | 地區 | 來源 | 來源日期 | 備註 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-01 | DualityBio | China | Adcendo ApS | DITAC linker-payload platform license (lead uPARAP ADC) | uPARAP | Preclinical | undisclosed | undisclosed | Undisclosed | www.biopharminternational.com | 2023-05-31 | Jan-2023 platform license referenced in May-2023 expansion release; exact day not confirmed |
| 2023-01-05 | IntoCell | South Korea | ADC Therapeutics | OHPAS linker / PMT payload technology (MTA + option, up to 6 targets) | Up to 6 undisclosed | Platform/preclinical | undisclosed | undisclosed | Worldwide | www.prnewswire.com | 2023-01-05 | Platform option deal; signing fee undisclosed |
| 2023-01-10 | Evopoint Biosciences | China | AmMax Bio | Novel solid-tumor ADC (unnamed), option | Undisclosed | Preclinical (not stated) | undisclosed | 871 | Worldwide ex Greater China | bioworld.com | 2023-01-10 | Option agreement; $871M total per ChemLinked roundup https://baipharm.chemlinked.com/news/chinese-antibody-drug-conjugates-adcs-licensed-overseas-exceeds-23-billion-this-year |
| 2023-01-10 | Ajinomoto Co. | Japan | Exelixis | AJICAP site-specific conjugation technology license | Undisclosed | Platform | undisclosed | undisclosed | Undisclosed | www.biospectrumasia.com | 2023-01-11 | Platform license; milestones + royalties, amounts undisclosed |
| 2023-02-13 | CSPC Megalith Biopharmaceutical (CSPC Pharma) | China | Corbus Pharmaceuticals | SYS6002 (CRB-701) | Nectin-4 | Phase 1 (China) | 7.5 | 692.5 | US, Canada, EU/EFTA, UK, Australia | www.sec.gov | 2023-02-13 | Milestones $130M dev/reg + $555M commercial |
| 2023-02-23 | KYM Biosciences (JV of Keymed 70% / Lepu Biopharma 30%) | China | AstraZeneca | CMG901 (AZD0901) | Claudin 18.2 | Phase 1 | 63 | 1163 | Worldwide | www.outsourcedpharma.com | 2023-02-23 | Milestones up to $1.1B; AZ 6-K: https://www.sec.gov/Archives/edgar/data/901832/000165495423001978/a7769q.htm |
| 2023-04 | GeneQuantum Healthcare | China | Pyramid Biosciences | GQ1010 | TROP2 | Preclinical | 20 | 1020 | Worldwide ex Greater China | bioworld.com | 2023-04 | Milestones up to $1B; exact day not confirmed |
| 2023-04 | MediLink Therapeutics | China | Zai Lab | ZL-1310 (YL212) | DLL3 | Preclinical | undisclosed | undisclosed | Worldwide | www.sec.gov | 2023-05-09 | Zai Lab Q1-2023 results release; Zai Lab is Shanghai/Cambridge MA; exact day not confirmed |
| 2023-04-03 | DualityBio | China | BioNTech | DB-1303 (BNT323) and DB-1311 (BNT324) | HER2; B7-H3 | Phase 2 (DB-1303); preclinical (DB-1311) | 170 | 1670 | Worldwide ex mainland China/HK/Macau | www.sec.gov | 2023-04-03 | Milestones 'over $1.5B' (total is lower bound); DualityBio US co-dev/co-promo option on DB-1311 |
| 2023-05-08 | BlissBio (Bliss Biopharmaceutical, Hangzhou) | China | Eisai | BB-1701 (eribulin payload) | HER2 | Phase 1/2 | undisclosed | 2000 | Option: worldwide ex Greater China | www.biospectrumasia.com | 2023-05-08 | Option-based co-development; upfront amount undisclosed |
| 2023-05-12 | Sino Biopharmaceutical (LaNova Medicines subsidiary) | China | AstraZeneca | LM-305 | GPRC5D | Preclinical/IND-cleared | 55 | 600 | Worldwide | www.biospace.com | 2023-05-12 | $55M = upfront + near-term combined; milestones up to $545M |
| 2023-05-30 | DualityBio | China | Adcendo ApS | MTA + option license for ADCs on 2 novel targets (DITAC platform) | 2 undisclosed | Preclinical | undisclosed | undisclosed | Undisclosed | www.biopharminternational.com | 2023-05-31 | Expansion of Jan-2023 platform license |
| 2023-07-10 | DualityBio | China | BeiGene (now BeOne Medicines) | Preclinical ADC option (later disclosed as B7-H4 ADC DB-1312/BG-C9074) | B7-H4 (not disclosed at signing) | Preclinical | undisclosed | 1300 | Worldwide (option) | www.businesswire.com | 2023-07-10 | Option-to-license; up to $1.3B contingent (lower bound, excl. upfront); option later exercised (https://www.thepharmaletter.com/beigene-exercises-option-on-dualitybios-b7h4-adc); BeiGene is China-founded |
| 2023-07-17 | GeneQuantum Healthcare | China | InxMed | Conjugation technology license | Undisclosed | Platform | undisclosed | undisclosed | Undisclosed | www.bioworld.com | 2023-07-18 | DOMESTIC China-China platform deal |
| 2023-08-07 | DualityBio | China | BioNTech | DB-1305 (BNT325) | TROP2 | Phase 1/2 | undisclosed | undisclosed | Worldwide ex mainland China/HK/Macau | www.drugdiscoveryonline.com | 2023-08-07 | Upfront + milestones + royalties, amounts undisclosed |
| 2023-10-12 | MediLink Therapeutics | China | BioNTech | YL202 (BNT326) | HER3 | Phase 1 | 70 | 1000 | Worldwide ex mainland China/HK/Macau | www.fiercebiotech.com | 2023-10 | Total 'more than $1B' (lower bound); date per ChemLinked roundup; also https://www.biospace.com/biontech-inks-potential-1b-deal-with-medilink-for-cancer-focused-adcs |
| 2023-10-19 | Daiichi Sankyo | Japan | Merck & Co. (MSD) | Patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd), raludotatug deruxtecan (R-DXd) | HER3; B7-H3; CDH6 | Phase 1-3 | 4000 | 22000 | Worldwide ex Japan (co-develop/co-commercialize) | www.daiichisankyo.com | 2023-10-20 | Plus $1.5B continuation payments over 24 months; coverage: https://www.biospectrumasia.com/news/25/23179/daiichi-sankyo-and-merck-announce-global-deal-worth-billion-dollars-to-develop-antibody-drug-conjugates.html |
| 2023-10-19 | Hummingbird Bioscience | Singapore | Endeavor BioMedicines | HMBD-501 (ENV-501) | HER3 | Preclinical | undisclosed | 430 | Worldwide | fiercebiotech.com | 2023-10-19 | Total incl upfront; date per BusinessWire https://www.businesswire.com/news/home/20231019896244/en |
| 2023-10-20 | Hansoh Pharma | China | GSK | HS-20089 | B7-H4 | Phase 1 (China) | 85 | 1570 | Worldwide ex mainland China/HK/Macau/Taiwan | www.gsk.com:443 | 2023-10-20 | Milestones up to $1.485B; HKEX https://www1.hkexnews.hk/listedco/listconews/sehk/2023/1020/2023102001151.pdf; terms confirmed via https://www.bioprocessintl.com/deal-making/gsk-forks-out-85m-for-hansoh-gynecology-cancer-adc |
| 2023-10-30 | Jiangsu Hengrui Pharmaceuticals | China | Merck KGaA (EMD) | SHR-A1904 (option) bundled with HRS-1167 (PARP1 inhibitor, licensed) | Claudin 18.2 (ADC); PARP1 (small molecule) | Phase 1 | 170 | 1530 | Worldwide ex China | www.emdgroup.com | 2023-10-30 | MIXED: EUR160M upfront (~US$170M per Invesco/GS table) and EUR1.4B total cover both assets incl non-ADC PARP1i; ADC is option-based |
| 2023-11-06 | Orum Therapeutics | South Korea | Bristol Myers Squibb | ORM-6151 program acquisition | CD33 antibody + GSPT1 degrader payload (degrader-antibody conjugate) | Phase 1 (IND cleared) | 100 | 180 | Worldwide (asset acquisition) | www.businesswire.com | 2023-11-06 | BORDERLINE modality: degrader-antibody conjugate; Orum is Daejeon/Boston |
| 2023-12-11 | SystImmune / Sichuan Biokin (Baili) | China | Bristol Myers Squibb | BL-B01D1 (izalontamab brengitecan) | EGFR x HER3 (bispecific ADC) | Phase 1 (US); later-stage in China | 800 | 8400 | US co-development/co-commercialization; BMS rest of world; Biokin retains mainland China | www.biopharminternational.com | 2023-12-19 | Plus up to $500M contingent near-term; milestones up to $7.1B; largest single-asset ADC upfront in dataset |
| 2023-12-15 | Harbour BioMed (Nona Biosciences) with MediLink | China | Pfizer | HBM9033 | Mesothelin (MSLN) | IND-cleared | 53 | 1103 | Worldwide | www.fiercebiotech.com | 2023-12-15 | $53M = upfront + near-term; milestones up to $1.05B; HKEX https://www1.hkexnews.hk/listedco/listconews/sehk/2023/1215/2023121500059.pdf |
| 2023-12-20 | Hansoh Pharma | China | GSK | HS-20093 (risvutatug rezetecan) | B7-H3 | Phase 1/2 (China) | 185 | 1710 | Worldwide ex mainland China/HK/Macau/Taiwan | www.gsk.com | 2023-12-20 | Milestones up to $1.525B; HKEX https://www1.hkexnews.hk/listedco/listconews/sehk/2023/1220/2023122000672.pdf |
| 2023-12-20 | AbTis | South Korea | Dong-A ST | Acquisition of control of AbTis (AbClick ADC linker platform) | n/a | Platform | undisclosed | undisclosed | n/a (M&A) | view.asiae.co.kr | 2023-12-20 | DOMESTIC Korea-Korea M&A; value undisclosed |
| 2023-12-20 | Escugen (Shanghai Escugen Biotechnology) | China | InxMed | EZWi-Fit linker-payload platform for several ADC candidates | Undisclosed TAAs | Platform | undisclosed | undisclosed | Undisclosed | www.pharmafocuseurope.com | 2023-12-20 | DOMESTIC China-China platform deal |
| 2023-12-21 | Pinotbio | South Korea | ConjugateBio (US) | PINOT-ADC camptothecin linker-payload platform (10 targets) | 10 undisclosed | Platform | undisclosed | 250 | Undisclosed | www.koreabiomed.com | 2023-12-21 | Total incl upfront; royalties extra |
| 2023-12-28 | LegoChem Biosciences (now LigaChem) | South Korea | Janssen (J&J) | LCB84 | TROP2 | Phase 1/2 | 100 | 1700 | Worldwide | www.biospectrumasia.com | 2023-12-28 | Total incl $200M option-exercise payment |
| 2024-01-02 | MediLink Therapeutics | China | Roche | YL211 | c-Met | Preclinical | 50 | 1050 | Worldwide | www.biospace.com | 2024-01-02 | $50M = upfront + near-term; milestones 'nearly $1B' (total approximate) |
| 2024-01-08 | Biocytogen Pharmaceuticals | China | Radiance Biopharma | HER2 x TROP2 bispecific ADC (option + license) | HER2 x TROP2 (bispecific ADC) | Preclinical | undisclosed | undisclosed | Worldwide | biocytogen.com | 2024-01-08 | Option fee undisclosed |
| 2024-04-03 | ProfoundBio | China/US (borderline) | Genmab | Company acquisition: Rina-S (PRO1184), PRO1160, PRO1107, PRO1286 | FRa; CD70; PTK7; EGFR x cMET | Phase 2 (Rina-S) | 1800 | 1800 | Worldwide (M&A) | www.sec.gov | 2024-04-03 | BORDERLINE origin: HQ Seattle with Suzhou R&D centre; all-cash acquisition; excluded from country totals in summary |
| 2024-05-26 | MediLink Therapeutics | China | BioNTech | TMALIN ADC platform - option on ADCs vs several novel targets | Several undisclosed | Discovery | 25 | 1800 | Worldwide (option); MediLink ROFN in Greater China | geneonline.com | 2024-06-06 | Milestones up to $1.8B (total is lower bound); Fierce: https://www.fiercebiotech.com/biotech/biontech-pays-25m-upfront-strengthen-adc-bond-chinas-medilink |
| 2024-06-05 | Alphamab Oncology | China | ArriVent BioPharma | Multi-target ADC discovery collaboration | Undisclosed | Discovery | undisclosed | 615.5 | Worldwide ex Greater China | www.sec.gov | 2024-06-05 | $615.5M incl upfront + milestones |
| 2024-06-18 | MabCare Therapeutics | China | Day One Biopharmaceuticals | MTX-13 (DAY301) | PTK7 | IND-cleared (Phase 1-ready) | 55 | 1207 | Worldwide ex Greater China | www.sec.gov | 2024-06-18 | Milestones up to $1.152B |
| 2024-07-11 | Foreseen Biotechnology | Taiwan | Ipsen | FS001 | Undisclosed novel TAA | Late preclinical | undisclosed | 1030 | Worldwide | www.drugdiscoveryonline.com | 2024-07-11 | $1.03B incl upfront; HQ Taipei per BioWorld (https://www.bioworld.com/keywords/53515-foreseen-biotechnology-co-ltd), though ChinaBioToday calls it Chinese; incubated by Nest.Bio Ventures |
| 2024-07-16 | Orum Therapeutics | South Korea | Vertex Pharmaceuticals | TPD2 degrader-antibody conjugate platform (up to 3 targets) | 3 undisclosed | Research | 15 | 945 | Worldwide | pmlive.com | 2024-07-18 | BORDERLINE modality (degrader-antibody conjugate); non-oncology (gene-editing conditioning) |
| 2024-07-31 | Biocytogen Pharmaceuticals | China | IDEAYA Biosciences | IDE034 B7-H3 x PTK7 topo-I bispecific ADC (option) | B7-H3 x PTK7 (bispecific ADC) | Preclinical | undisclosed | 406.5 | Worldwide (on option exercise) | chambers.com | 2025-04-25 | Total incl upfront, option exercise and milestones |
| 2024-08-20 | Multitude Therapeutics | China | Adcendo ApS | AMT-754 (ADCE-T02) | Tissue factor | Preclinical (CTA filed) | undisclosed | 1000 | Worldwide ex mainland China/HK/Macau/Taiwan | pharmaphorum.com | 2024-08-20 | Total 'above $1B' (lower bound); upfront reportedly 'tens of millions' (not disclosed) |
| 2024-10-10 | LigaChem Biosciences | South Korea | Ono Pharmaceutical | LCB97 + research collaboration on Ono-selected targets (ConjuAll platform) | L1CAM | Preclinical | undisclosed | 700 | Worldwide | prd.ono-pharma.com | 2024-10-10 | Coverage: https://www.fiercebiotech.com/biotech/ono-links-ligachem-bag-preclinical-adc-700m-biobuck-deal |
| 2024-11-19 | VelaVigo | China | Avenzo Therapeutics | Nectin-4 x TROP2 bispecific ADC (option) | Nectin-4 x TROP2 (bispecific ADC) | Preclinical | undisclosed | 800 | Worldwide ex Greater China | www.pharmafocusasia.com | 2024-11-19 | Up to $50M option-related + ~$750M milestones (approximate) |
| 2024-12-03 | DualityBio | China | GSK | DB-1324 (option) | Undisclosed GI-cancer target | Preclinical | 30 | 1005 | Worldwide ex mainland China/HK/Macau | www.drugdiscoveryonline.com | 2024-12-03 | $30M = upfront + pre-option milestones; milestones up to $975M + undisclosed option fee (total lower bound) |
| 2024-12-19 | Hangzhou DAC Biotechnology (with WuXi Biologics) | China | Aadi Bioscience (now Whitehawk Therapeutics) | PTK7-CPT113, mMUC16-CPT113, biSEZ6-CPT113 | PTK7; MUC16; SEZ6 | Preclinical | 44 | 893 | Worldwide | www.sec.gov | 2024-12-19 | Milestones up to $849M |
| 2024-12-29 | Jiangsu Hengrui Pharmaceuticals | China | IDEAYA Biosciences | SHR-4849 (IDE849) | DLL3 | Phase 1 | 75 | 1045 | Worldwide ex Greater China | www.sec.gov | 2024-12-29 | |
| 2025-01-02 | Innovent Biologics | China | Roche | IBI3009 | DLL3 | Phase 1 | 80 | 1080 | Worldwide | www.drugdiscoveryonline.com | 2025-01-02 | Milestones up to $1.0B |
| 2025-01-07 | DualityBio | China | Avenzo Therapeutics | AVZO-1418 / DB-1418 | EGFR x HER3 (bispecific ADC) | Preclinical (IND-enabling) | 50 | 1200 | Worldwide ex Greater China | www.businesswire.com | 2025-01-07 | Milestones up to ~$1.15B |
| 2025-01-09 | MediLink Therapeutics | China | Zai Lab | ZL-6201 (Zai antibody + MediLink TMALIN platform) | LRRC15 | Preclinical | undisclosed | undisclosed | Worldwide | www.businesswire.com | 2025-01-09 | Platform-based collaboration/license |
| 2025-01-22 | Lepu Biopharma | China | ArriVent BioPharma | MRG007 | CDH17 | Phase 1-ready (IND planned) | 47 | 1207 | Worldwide ex Greater China | medcitynews.com | 2025-01-22 | $47M = upfront + near-term per Lepu FY2025 results (https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0325/2026032500375.pdf); milestones up to $1.16B; target confirmed in HKEX filing |
| 2025-02-19 | CSPC Megalith Biopharmaceutical (CSPC Pharma) | China | Radiance Biopharma | SYS6005 (RB-164) | ROR1 | Phase 1 (China) | 15 | 1165 | US, Canada, EU, UK, Switzerland, EEA states, Western Balkans, Australia | www.biospace.com | 2025-02-20 | $150M dev/reg + >$1B commercial milestones (total lower bound) |
| 2025-03-03 | Hummingbird Bioscience | Singapore | Callio Therapeutics (newco) | Multi-payload ADC platform + related IP and pipeline assets | Undisclosed (Callio lead: HER2 dual-payload ADC) | Preclinical | undisclosed | undisclosed | Worldwide | www.biospectrumasia.com | 2025-03-04 | Newco structure; Hummingbird receives equity + milestones/royalties; Callio raised $187M Series A |
| 2025-05-09 | Minghui Pharmaceutical | China | Qilu Pharmaceutical | MHB088C | B7-H3 | Phase 3 (China SCLC) | 38 | 185 | Greater China only | www.biospace.com | 2025-05-09 | DOMESTIC China-China; RMB280M upfront, up to RMB1.345B total; USD per Fierce https://www.fiercebiotech.com/biotech/qilu-pharmaceutical-pays-38m-upfront-greater-china-rights-minghuis-adc-cancer-drug |
| 2025-05-29 | Evopoint Biosciences | China | Astellas Pharma | XNW27011 | Claudin 18.2 | Phase 1/2 (China) | 130 | 1340 | Worldwide ex mainland China/HK/Macau/Taiwan | medcitynews.com | 2025-05-30 | Plus up to $70M near-term |
| 2025-06-16 | Simcere Zaiming (Simcere Pharmaceutical) | China | NextCure | SIM0505 (+ linker-payload license for a NextCure-target ADC) | CDH6 | Phase 1 (China) | undisclosed | 745 | Worldwide ex Greater China | ir.nextcure.com | 2025-06-16 | Co-development partnership; total incl upfront |
| 2025-09-24 | Jiangsu Hengrui Pharmaceuticals | China | Glenmark Pharmaceuticals | SHR-A1811 (trastuzumab rezetecan) | HER2 | Approved (China) | 18 | 1111 | Emerging markets (excludes Greater China, US, Canada, Europe, Japan, Russia/CIS) | www.biospectrumasia.com | 2025-09-24 | Regional commercial license |
| 2025-10-16 | Hansoh Pharma | China | Roche | HS-20110 | CDH17 | Phase 1 | 80 | 1530 | Worldwide ex mainland China/HK/Macau/Taiwan | filingreader.com | 2025-10-16 | Milestones up to $1.45B |
| 2025-10-17 | AimedBio | South Korea | Boehringer Ingelheim | Undisclosed exatecan-derivative ADC (reported as AMB302) | Undisclosed (reported FGFR3) | Preclinical (not stated) | undisclosed | 991 | Worldwide | www.biospectrumasia.com | 2025-10-17 | Target not named in release; FGFR3/AMB302 per Korean press (unverified) |
| 2025-10-21 | Innovent Biologics | China | Takeda | IBI343 (license) + IBI3001 (option) [deal also covers non-ADC IBI363] | Claudin 18.2; EGFR x B7-H3 (bispecific ADC) | Phase 3 (IBI343); Phase 1 (IBI3001) | 1200 | 11400 | Worldwide ex Greater China (ADCs) | www.biospace.com | 2025-10-22 | MIXED: $1.2B upfront (incl $100M equity) and $11.4B total cover whole deal incl PD-1/IL-2 bispecific IBI363; not split per asset |
| 2025-10-31 | Ajinomoto Co. | Japan | Astellas Pharma | AJICAP site-specific conjugation technology license | Undisclosed | Platform | undisclosed | undisclosed | Undisclosed | www.pharmamanufacturing.com | 2025-10-31 | DOMESTIC Japan-Japan platform deal |
| 2025-11-19 | Triore (TriOar) | South Korea | Celltrion | TRACAD conditionally-activatable ADC platform (up to 6 targets) | Up to 6 undisclosed | Platform | undisclosed | 356 | Undisclosed | www.1stoncology.com | 2025-11-19 | DOMESTIC Korea-Korea; ~KRW522B if all 6 targets exercised |
| 2025-12-04 | Kelun-Biotech | China | Crescent Biopharma | SKB105 (CR-003) | ITGB6 | Preclinical | 80 | 1330 | Worldwide ex Greater China | www.sec.gov | 2025-12-04 | Milestones up to $1.25B; reciprocal: Kelun in-licensed CR-001 (PD-1xVEGF) for Greater China ($20M upfront to Crescent); closing announced Jan 2026 |
| 2026-01-08 | Biocytogen Pharmaceuticals | China | Acepodia (Taiwan/US) | Two bispecific ADC programs for dual-payload (BsAD2C) development (option) | Undisclosed (bispecific ADC) | Preclinical | undisclosed | undisclosed | Worldwide (on option exercise) | www.businesswire.com | 2026-01-08 | Option fee undisclosed |
| 2026-01-12 | MediLink Therapeutics | China | Roche | YL201 (tambotatug pelitecan) | B7-H3 | Phase 3 (China) | 570 | undisclosed | Worldwide ex mainland China/HK/Macau | www.biospectrumasia.com | 2026-01-12 | $570M = upfront + near-term milestones combined; further milestones undisclosed (total >= $570M) |
| 2026-01-13 | OBI Pharma | Taiwan | TegMine Therapeutics | Glycan-targeting ADC (TegMine antibody + OBI GlycOBI/Obrion ADC technology) | Cancer-associated glycans | Preclinical | undisclosed | undisclosed | Worldwide | www.biospectrumasia.com | 2026-01-13 | Follows Jun-2025 master services agreement |
| 2026-05-28 | Innovent Biologics | China | Pfizer | 8 Innovent early-stage oncology programs (novel-payload ADCs + multispecifics) within a 12-program pact | Undisclosed | Discovery/early stage | 650 | 10500 | Mixed: 4 programs global, 4 ex-Greater China, 4 US/EU co-dev | medcitynews.com | 2026-05-29 | MIXED: ADC share of the 12 programs not disclosed |
| 2026-07-22 | IntoCell | South Korea | Samsung Bioepis | SBE303 commercial license (IntoCell linker-payload) | Nectin-4 | Phase 1 | undisclosed | undisclosed | Undisclosed | www.thepharmaletter.com | 2026-07-22 | DOMESTIC Korea-Korea; follows Dec-2023 research pact; target per https://en.edaily.co.kr/news/eda202607225714 |
| 2026-08-03 | Alphamab Oncology | China | Pathos AI | JSKN016 | TROP2 x HER3 (bispecific ADC) | Phase 3 (China) | 125 | 2218 | Worldwide ex mainland China/HK/Macau/Taiwan | www.fiercebiotech.com | 2026-08-03 | Milestones up to $2.093B; HKEX https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0804/2026080400073.pdf; terms per https://www.biobucks.co/biotech-bdl-tracker-2026 Deal data |
| 2026-08-28 | DualityBio | China | Genentech (Roche) | DUPAC payload platform ADCs (lead payload DUP5) | Undisclosed (Genentech-selected) | Discovery | 45 | 1045 | Worldwide | www.biopharminternational.com | 2026-08-28 | Milestones 'more than $1B' (total lower bound); HKEX https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0828/2026082800097.pdf Deal data |
| 2026-09-03 | HUTCHMED | China | GSK | HMPL-A830 (antibody-targeted therapy conjugate) | EGFR antibody + KRAS-inhibitor payload | Preclinical (Ph1 2H26) | 110 | 1295 | Worldwide ex mainland China/HK/Macau/Taiwan | www.sec.gov | 2026-09-03 | BORDERLINE modality (non-cytotoxic small-molecule payload); total incl upfront |
| 2026-09-17 | WuXi XDC | China | Ona Therapeutics | WuXiTecan-2 payload-linker platform for one ADC | 1 undisclosed | Discovery | undisclosed | undisclosed | Worldwide | www.biospectrumasia.com | 2026-09-17 | Payload-linker technology license |
| 2026-10-09 | MicuRx Pharmaceuticals | China | ClearideBio Therapeutics AG | MRX-23 (license) + STOPIN platform option on up to 6 targets | HER2 (MRX-23) | Preclinical | 1 | 223 | Worldwide | www.vcbeathealth.com | 2026-10-10 | MRX-23 total up to $223M; separate platform option cap up to $750M cumulative; announced as planned signing |
| 2026-10-15 | Pinotbio | South Korea | Alentis Therapeutics | Option to license PINOT linker-payloads for Alentis ADC candidates | Claudin-1 | Preclinical | undisclosed | undisclosed | Undisclosed | www.pharmaceutical-technology.com | 2026-10-15 | |
| 2026-10-19 | Hansoh Pharma | China | Roche | 2 preclinical ADC programs + ADCs vs Roche-nominated targets (Hansoh ADC platform) | Undisclosed | Preclinical/discovery | 400 | 15510 | Worldwide ex mainland China/HK/Macau/Taiwan | www.pharmexec.com | 2026-10-19 | Plus $110M fixed first-anniversary payment; milestones >$15B (total lower bound); Hansoh option on up to 2 programs; HKEX https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1019/2026101900015.pdf Deal data |
Frequently asked questions
Which Asian company leads in ADCs?
Daiichi Sankyo, with two US-approved ADCs (Enhertu and Datroway) and three more in Phase 3 partnered with Merck & Co., as of November 2026.
Which Chinese company has the most late-stage ADCs?
Jiangsu Hengrui, with one approved ADC (SHR-A1811) and five ADCs in Phase 3, as of November 2026.
Has any China-originated ADC been approved by the FDA?
Not as of November 2026. Kelun-Biotech and Merck's sacituzumab tirumotecan has a US decision date of June 15, 2027.
What was the largest Asian ADC licensing deal since 2023?
Daiichi Sankyo–Merck & Co. in October 2023: $4.0 billion upfront and up to $22 billion in total for three ADCs. The largest from a Chinese company was SystImmune–Bristol Myers Squibb in December 2023, with $800 million upfront.
Which Taiwanese companies are developing ADCs?
OBI Pharma leads with OBI-992 (TROP2) in Phase 1/2. See our Taiwan ADC companies map.
Methodology: assets ranked by highest development stage; deals limited to an Asian licensor or seller, January 1, 2023 to October 31, 2026; upfronts as disclosed, with mixed non-ADC bundles flagged. Full asset and deal tables, with sources, are published on this page and updated monthly. This is industry analysis, not investment advice.
